$WEYL The integration of the Weyland and Push platforms is

New Post Public Reply Private Reply Replies (0) Message Board
Lets Roll
159
$WEYL The integration of the Weyland and Push platforms is expected to significantly enhance the value proposition for existing and prospective customers. Initial cross-selling opportunities include using CreateApp and AtozPay to support U.S.-based projects and campaigns for Push’s current enterprise customers.

“We recognized tremendous synergies in technology and in our corporate missions right from the start,” commented Haig Newton, co-founder, CEO and president of Push Holdings. “We believe that together we will be able to better help businesses and brands around the world reach more customers, increase their sales, and promote their products and services in an easier, more affordable and highly efficient way.”

Push will provide Weyland a well-established beachhead in North America, allowing it to attract new users to CreateApp and AtozPay quickly and cost-efficiently. This includes greatly reduced customer acquisition costs Weyland could not have achieved on its own. Previously, U.S. customer acquisition costs for CreateApp were estimated at $2-$3 per dollar generated, making market entry economically unfeasible. By leveraging Push’s highly effective marketing technology and operational resources, U.S. customer acquisition cost is expected to be as little as $0.30 on the dollar.

“What we find so amazing about CreateApp is that it requires literally no technical understanding or skills in app design for anyone to build a full-featured custom app in less than two hours,” noted Push Interactive’s chief technology officer, Tom Furukawa. “It’s a Shopify-like solution for mobile that enables businesses and brands to establish a mCommerce presence in an intuitive, do-it-yourself fashion. Layering on our Push platform, CreateApp users gain a fully end-to-end mCommerce solution supported by our team of expert digital media marketers that can enhance their visibility, customer traffic and ultimately conversions.”

As part of a public company, Weyland’s new Push subsidiary will gain easier access to growth capital and be better able to attract additional employee talent. Push can also leverage the cost efficiencies and diverse capabilities of Weyland’s existing 200-person technology and software development team in Jaipur, India, while Weyland gains technical and software development expertise from Push.

Weyland plans to launch CreateApp in the U.S. during the first quarter of 2020. The North American market is expected to support a higher price point for subscription fees as compared to the company’s current market in Southeast Asia. A comparative revenue model of a U.S. industry peer supports 96,000 users at $300 each per month. This is several times higher than the current CreateApp subscription model for Southeast Asia at only $12-$80 per month, depending on optional features implemented.

“Our initial work with Push to introduce CreateApp in the U.S. led to this strategic acquisition, so we have already made strong progress in this regard,” added Suen. “eCommerce is becoming increasingly mobile in the U.S., creating a huge new market opportunity for CreateApp and AtozPay.”

Weyland’s post-acquisition revenue model anticipates that U.S. CreateApp subscription revenues alone could exceed $5 million by end of 2020. This would be in addition to potential new Push offerings adopted by Weyland’s existing international SMB customer base, as well as new AtozPay eWallet and mobile pay integrations in the U.S.

Additional details about the definitive asset purchase agreement are provided in a Form 8-K, available at www.sec.gov and the investor relations section of Weyland Tech’s website at weyland-tech.com.

https://www.bloomberg.com/press-releases/2019...25-million
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 5

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading

Top 5 Most Recently Viewed Articles

BioCryst Pharmaceuticals Reports Positive Outcomes for ORLADEYO

Updated Category News Views 62

BioCryst Pharmaceuticals Highlights ORLADEYO's Impact BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has unveiled a compelling study that underscores how ORLADEYO (berotralstat) significantly lowers healthcare resource utilization (HRU) for patients battling hereditary angioedema (HAE). This innovative oral treatment has garnered attention due to its remarkable findings,...

Continue Reading
Man Group PLC Discloses Interest in Spectris plc Shares

Updated Category News Views 174

Understanding Man Group PLC's Position Disclosure Man Group PLC is making headlines as it officially discloses its holdings in Spectris plc. This disclosure is known as FORM 8.3 and is a crucial document under Rule 8.3 of the Takeover Code. It indicates the shareholding interests of Man Group in Spectris, representing a significant percentage of the company's relevant...

Continue Reading
Centessa Pharmaceuticals Seeks $225 Million Through Public Offering

Updated Category News Views 91

Centessa Pharmaceuticals Launches Major $225 Million Offering Centessa Pharmaceuticals plc (NASDAQ: CNTA), an innovative clinical-stage pharmaceutical company, has announced an ambitious public offering with the goal of raising around $225 million. This offering features 15,254,237 American Depositary Shares (ADSs), each representing one ordinary share, priced at $14.75...

Continue Reading
Unveiling Software Giants: Microsoft and Its Rivals in 2024

Updated Category News Views 350

Understanding the Competitive Landscape of Software Giants In the dynamic world of software, staying informed about leading companies is vital for investors and analysts alike. This article focuses on Microsoft (NASDAQ: MSFT) and its primary competitors, aiming to deliver a thorough analysis of financial statistics, market standings, and opportunities for growth within...

Continue Reading
Harris Leads Trump by 3 Points in Key Election Polls

Updated Category News Views 105

Election Polls Show Harris's Slim Lead Over Trump In the battleground of the upcoming U.S. presidential election, Democratic Vice President Kamala Harris has established a slender lead over Republican contender Donald Trump, according to the latest polling data. Recent surveys indicate that Harris is ahead by a margin of 3 points, with her support reaching 45% compared to...

Continue Reading